Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology (NASDAQ: CRDF) reported positive Phase 2 CRDF-004 results for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). In an intent-to-treat analysis (data cut Jan 22, 2026) the 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a confirmed objective response rate of 72.2% versus 43.2% for pooled standard of care, and a PFS hazard ratio 0.37 vs SoC (p=0.048) with median PFS not reached versus 10.97 months for SoC. Safety was manageable with no major additive toxicity. The company selected the 30 mg dose for a planned registrational program and expects final data and registrational plans in H1 2026.
Cardiff Oncology (Nasdaq: CRDF) announced executive leadership changes effective January 27, 2026, as it transitions toward late-stage clinical development. Mani Mohindru, PhD, a board member since 2021, was appointed interim CEO effective immediately. Mark Erlander, PhD, and James Levine stepped down as CEO and CFO. Brigitte Lindsay was promoted to Chief Accounting Officer after 14+ years with the company. The company has initiated searches for permanent CEO and CFO roles. Cardiff’s lead candidate, onvansertib, is in mid-stage development for RAS-mutated metastatic colorectal cancer and is being evaluated in multiple investigator-initiated studies across other tumor types.
Cardiff Oncology (Nasdaq: CRDF) announced clinical data from an investigator-sponsored Phase 1 poster on onvansertib in chronic myelomonocytic leukemia (CMML) to be presented at ASH 2025.
In a dose-escalation trial (N=9), onvansertib monotherapy was reported as relatively well-tolerated and showed preliminary efficacy in approximately 40% of patients, with one patient achieving an optimal marrow response at the 9 mg/m2 dose. The company is not currently planning to develop onvansertib for CMML.
Poster details: Dec 8, 2025, 6:00-8:00 PM EST; Speaker: Mrinal Patnaik, MD; Session 637, Poster III.
Cardiff Oncology (Nasdaq: CRDF) will present at Sidoti’s Year-End Virtual Investor Conference on December 11, 2025 at 4:00 PM ET. CEO Mark Erlander, PhD will deliver the presentation and host one-on-one meetings during the conference running December 10–11, 2025. Interested parties can register and access the live webcast via the company’s Events section. A webcast replay will be available after the presentation.
Cardiff Oncology (Nasdaq: CRDF) will present at the Piper Sandler 37th Annual Healthcare Conference, held December 2–4, 2025. Company management will participate in a fireside chat and 1x1 investor meetings.
Presenter: Mark Erlander, PhD, CEO. Presentation date/time: December 2, 2025 at 9:30 AM ET. Interested parties can register and watch a live webcast via the company’s Events page, and a replay will be available after the presentation.
Cardiff Oncology (Nasdaq: CRDF) reported Q3 2025 results and a business update on Nov 6, 2025. The company announced positive Phase 2 CRDF-004 data for onvansertib plus standard of care in first-line RAS-mutated metastatic colorectal cancer, citing a 19% improvement in confirmed ORR for the 30mg cohort at the July 8, 2025 data cut-off and early PFS separation favoring 30mg.
Cardiff reported $60.6 million in cash and investments as of Sept 30, 2025, net cash used in operating activities of $10.8 million in Q3 2025, and projects runway into Q1 2027. A clinical update is expected in Q1 2026.
Cardiff Oncology (Nasdaq: CRDF) announced management will participate in two investor conferences in November 2025. CEO Mark Erlander, PhD will appear at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on 11/11/2025 at 9:30 AM ET for a fireside chat and 1x1 meetings, and at the Stifel 2025 Healthcare Conference on 11/12/2025 at 9:20 AM ET for a corporate presentation and 1x1 meetings.
Interested parties can register and access live webcasts via the company’s Events page; replay will be available after each presentation.
Cardiff Oncology (Nasdaq: CRDF) announced management will participate in two virtual investor conferences on October 9, 2025. A Piper Sandler Virtual Oncology Symposium fireside chat will feature Mark Erlander, PhD (CEO), James Levine (CFO) and Roger Sidhu, MD (CMO) at 1:00 PM ET. A Noble Capital Markets Emerging Growth Virtual Equity Conference fireside chat will feature Mark Erlander at 2:00 PM ET.
Attendance instructions: contact Piper Sandler for access; Noble registration is free. A webcast replay will be posted within 48 hours in the Events section of Cardiff Oncology’s website.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in three major investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference (09/05), the Morgan Stanley Global Healthcare Conference (09/08), and the H.C. Wainwright Global Investment Conference (09/09). CEO Mark Erlander will present a fireside chat at the H.C. Wainwright conference at 10:30 AM ET, which will be available via webcast on the company's website.
Cardiff Oncology (Nasdaq: CRDF) announced positive data from its Phase 2 clinical trial evaluating onvansertib combined with standard-of-care (SoC) for first-line RAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated a 49% confirmed objective response rate (ORR) in the 30mg onvansertib arm versus 30% in the control arm.
Key highlights include:
- Dose-dependent response across all endpoints including ORR, early tumor shrinkage, and depth of response
- Early PFS data showing favorable trend for 30mg onvansertib dose
- Well-tolerated safety profile with neutropenia as the most common treatment-emergent adverse event
The company plans to engage with FDA regarding the registrational CRDF-005 trial and expects to provide a program update by Q1 2026.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
